Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Methods and Compositions of Viral Chemokine-Antigen Fusion Proteins as Vaccines for Tumors and AIDS

Description of Invention:
Tumor antigens are known to be poorly immunogenic and attempts to elicit immune responses against the epitopes of antigens specific to tumor cells have been largely unsuccessful. The inventors have developed a cancer vaccine comprising a tumor antigen fused with a human chemokine or viral antigen to enhance the immunogenicity of the tumor antigen or viral antigen. The inventors have demonstrated, with animal data, that chimeric proteins, comprising a viral chemokine fused to a model tumor antigen (lymphoma-derived single-chain Fv), when administered to a subject, generate a measurable humoral and anti-tumor cellular immune response.

Inventors:
Arya Biragyn and Larry W. Kwak (NCI)

Patent Status:
DHHS Reference No. E-194-2000/0
U.S. Provisional Application No. 60/233,067 filed 15 Sep 2000
PCT Application No. PCT/US01/29075 filed 15 Sep 2001
U.S. Patent Application No. 10/380,927 filed 17 Mar 2003

Portfolios:
Cancer

Cancer -Therapeutics-Vaccines
Cancer -Therapeutics


For Additional Information Please Contact:
Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220


Web Ref: 176

Updated: 12/00

 

 
 
Spacer